AXS-12 (reboxetine)

DRUG3 trials

Sponsors

Axsome Therapeutics, Inc.

Conditions

CataplexyCataplexy NarcolepsyExcessive Daytime SleepinessExcessive SleepinessNarcolepsy

Phase 2

Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)

CompletedNCT03881852

Axsome Therapeutics, Inc.Cataplexy Narcolepsy, Excessive Sleepiness, Narcolepsy

Start: 2019-04-05End: 2019-11-27Updated: 2026-06-15

Phase 3

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

CompletedNCT05059223

Axsome Therapeutics, Inc.Cataplexy, Excessive Daytime Sleepiness, Narcolepsy

Start: 2021-09-15End: 2024-03-15Updated: 2026-05-28

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

CompletedNCT05113745

Axsome Therapeutics, Inc.Cataplexy, Excessive Daytime Sleepiness, Narcolepsy

Start: 2021-10-20End: 2024-11-15Updated: 2025-11-13